Plasminogen activator inhibitor-1 levels and polymorphisms: Association with venous thromboembolism

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 11, 2002, Pages 1401-1404

  Francis, Charles W ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACUTE PHASE RESPONSE; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; PRACTICE GUIDELINE; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

BLOOD COAGULATION TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0036881059     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Stiko A, Hervio L, Loskutoff DJ. Plasminogen activator inhibitors. In: Coleman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:975-1002.
2. Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. In: Coleman RW, Hirsh J, Marder VJ, Clowes George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:355-365.
3. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type I plasminogen activator inhibitor. J Clin Invest. 1989;83:1747-1756.
4. Fay WP, Shapiro AD, Shih JL, et al. Brief report: complete deficiency of plasminogen-activator inhibitor type I due to a frame-shift mutation. N Engl J Med. 1992;327:1729-1732.
5. Erickson LA, Fici GJ, Lund JE, et al. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 1990;346: 74-79.
6. Carmeliet P, Stassen JM, Van Vlaenderen I, et al. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood. 1997;90:1527-1534.
7. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517-1532.
8. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator increased concentration of plasminogen activator inhibitor. BMJ. 1985;290:1453-1456.
9. Wiman B, Ljungberg B, Chmielewskaj, et al. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med. 1985;105:265-270.
10. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep vein thrombosis. Thromb Haemost. 1987;57:67-72.
11. Nguyen G, Horellou MH, Kruithof EKO, et al. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis. Blood. 1988;72:601-605.
12. Johansson L, Hedner U, Nilsson IM. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand. 1978;203:477-480.
13. Jorgensen M, Mortensen JZ, Madsen AG, et al. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis. Scand J Haematol. 1982;29:217-223.
14. Jorgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol. 1987;65:175-180.
15. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism: Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost. 1996;75:607-611.
16. Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost. 2001;85:390-394.
17. Mansfield MW, Stickland MH, Grant PJ. PAl-1 concentrations in first degree relative of patients with non-insulin-dependent diabetes mellitus: metabolic and genetic associations. Thromb Haemost. 1999;77:357-361.
18. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11: 183-190.
19. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin J. Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes. 1995;44:37-42.
20. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 promoter polymorphisms and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost. 1995;74:1032-1034.
21. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphisms in the promoter of the plasminogen activator inhibitor-1 (PAl-1) gene is associated with differences in plasma PAl-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost. 1995;74:837-841.
22. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allelespecific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995; 92:1851-1855.
23. Burzotta F, DiCastelnuovo A, Amore A, et al. 4G/5G promoter PAl-1 gene polymorphism is associated with plasmatic PAl-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost. 1998;79:354-358.
24. Margaglione M, Grandone E, Vecchione G, et al. Plasminogen activator inhibitor-1 (PAl-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAl-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol. 1997;17:2082-2087.
25. Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res. 1996;84:431-443.
26. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM. 4G/5G polymorphism of PAl-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost. 1998;80:956-960.
27. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JR Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59-62.
28. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAl-1) gene: relationship to plasma PAl-1 level in venous thromboembolism. Thromb Haemost. 1998;79: 975-979.
29. Hooper WC, Lally C, Austin H, et al. The role of the t-PA I/D and PAl-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res. 2000;99:223-230.
30. Akar N, Yilmaz E, Akar E, Avcu F, Yalcin A, Cin S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. Thromb Res. 2000;97:227-230.
31. Segui R, Estellés A, Mira Y, et al. PAl-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol. 2000;111:122-128.
32. Zöller B, García de Frutos P, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAl-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost. 1998;79:802-807.
33. Junker R, Nabavi DG, Wolff E, et al. Plasminogen activator inhibitor-1 4G/ 4G-genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost. 1998;80:706-707.
34. Morange PE, Henry M, Tregouët D, et al. The A-844G polymorphism in the PAl-1 gene is associated with high risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol. 2000;20:1387-1391.
35. Tassies D, Espinosa G, Muñoz-Rodriguez FJ, et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum. 2000;43:2349-2358.
36. Kluft C. Criteria and search for specific assays for active plasminogen activator inhibitor 1 (PAl-1) in plasma. eJIFCC [serial online]. Available at: www.ifcc.org/ejifcc/vol12no1/PAl-1assays.htm. Accessed June 14, 2002.
37. Olson JD. College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia: introduction and general considerations. Arch Pathol Lab Med. 2002;126:1277-1280.